Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE10A | Q9Y233 | 9/20 | 0.41 |
| ▸ | AAK1 | Q2M2I8 | 3/20 | 0.40 |
| ▸ | HTR3A | P46098 | 1/20 | 0.32 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.32 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.32 |
| ▸ | TYMS | P04818 | 1/20 | 0.31 |
| ▸ | PIM1 | P11309 | 1/20 | 0.31 |
| ▸ | PIM2 | Q9P1W9 | 1/20 | 0.31 |
| ▸ | CTNNB1 | P35222 | 1/20 | 0.31 |
| ▸ | TCF7L2 | Q9NQB0 | 1/20 | 0.31 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17653260 | 0.88 | PDE10A (0.41) | PDE10AAAK1EGLN1 | |
| SCHEMBL17653174 | 0.81 | PDE10A (0.44) | PDE10AAAK1 | |
| SCHEMBL17653415 | 0.80 | AAK1 (0.40) | AAK1HTR3AHRH4IRAK4TYMS | |
| SCHEMBL17653149 | 0.80 | AAK1 (0.43) | AAK1TYMS | |
| SCHEMBL17653224 | 0.80 | AAK1 (0.40) | AAK1TYMS | |
| SCHEMBL17653304 | 0.72 | AAK1 (0.65) | AAK1 | |
| SCHEMBL17653155 | 0.70 | TUBB4A (0.43) | PDE10AAAK1TYMSPIM1PIM2 | |
| SCHEMBL17653401 | 0.69 | AAK1 (0.57) | PDE10AAAK1IRAK4 | |
| SCHEMBL31031354 | 0.68 | CYP1A2 (0.55) | IRAK4 | |
| SCHEMBL17653201 | 0.68 | AAK1 (0.40) | AAK1HTR3AHRH4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170239249-A1 | QUINAZOLINE-BASED KINASE INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2017-08-24 | — | — | US | disclosed |
| US-20170239249-A1 | QUINAZOLINE-BASED KINASE INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2017-08-24 | — | — | US | disclosed |
| US-20170239249-A1 | QUINAZOLINE-BASED KINASE INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2017-08-24 | — | — | US | disclosed |
| EP-3200797-A1 | QUINAZOLINE-BASED KINASE INHIBITORS | Bristol-Myers Squibb Company (US) | 2017-08-09 | — | — | EP | disclosed |
| WO-2016053794-A1 | QUINAZOLINE-BASED KINASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2016-04-07 | — | — | WO | disclosed |
| WO-2016053794-A1 | QUINAZOLINE-BASED KINASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2016-04-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170239249-A1 | QUINAZOLINE-BASED KINASE INHIBITORS | AAK1, ULK1, NCK1 | PDE10A 3746/4885AAK1 1/4885HTR3A 2832/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.